Abstracts

711 – Potent, Pan-Coronavirus Antiviral Activity of the Novel 3CLpro Inhibitor ALG-097558

Background Despite widespread immunity from SARS-CoV-2 vaccination and/or past infection, safe, effective, and convenient treatments for acute infection are still needed for individuals who remain at high risk for disease progression. Moreover, the risk of another coronavirus pandemic is an ongoing threat to global health. In this context, the development of pan-coronavirus therapeutics is a…

661 – Switch to DTG/3TC vs B/F/TAF (PASO-DOBLE Study): Efficacy and Weight Changes by Predefined Subgroups

Background The PASO-DOBLE study (ClinicalTrials.gov NCT04884139) demonstrated non-inferior efficacy and less weight gain when switching to DTG/3TC vs BIC/FTC/TAF in virologically suppressed people with HIV (PWH). We planned to assess subgroup analyses of efficacy (HIV RNA <50 copies/mL at 48 weeks) and clinically meaningful weight changes (>5% from baseline) by predefined baseline demographic, clinical and treatment characteristics. …

640 – Preclinical Pharmacokinetic Assessment of a Long-Acting Solid Injectable for Hepatitis C Virus

Background Approximately 58 million people are chronically infected with HCV globally, with approximately 1.5 million new infections per year and a disproportionate burden in low- and middle-income countries. Approved oral treatments, administered over 8 – 12 weeks, are highly effective demonstrating >98% sustained virological response (SVR) in RCTs. However, in some populations intention to treat…

646 – TAF Achieves Adequate Intracellular Tenofovir-DP Concentrations With Rifampicin-Based TB Therapy

Background Co-administration of rifampicin with tenofovir alafenamide fumarate (TAF) significantly reduces plasma tenofovir and intracellular tenofovir diphosphate (TFV-DP) concentrations. Standard dose TAF with rifampicin (RIF) was associated with TFV-DP concentrations that were markedly higher than those observed with tenofovir disoproxil fumarate (TDF) without rifampicin in healthy volunteers, however, data from people with TB/HIV-1 are needed…

651 – Tenofovir Diphosphate in Dried Blood Spots and HIV-1 RNA Suppression Among PWH on TAF (ACT Study)

Background ACT (NCT05335590) is an ongoing observational study that aims to evaluate tenofovir-diphosphate (TFV-DP) concentrations in dried blood spots (DBS) among persons with HIV (PWH) receiving tenofovir alafenamide (TAF)-based antiretroviral therapy (ART) with suppressed compared with detectable HIV-1 RNA. Previously, QUANTI-TAF (NCT04065347) reported a pharmacokinetic (PK)-based TFV-DP in DBS benchmark of ≥1800 fmol/punches for PWH…

639 – First-in-Human Study of a Long-Acting Injectable 3 Antiretroviral Drug Combination Nanoparticle

Background Long-Acting antiretroviral therapy (LA-ART) is considered an integral tool to improve adherence and decrease stigma, but its global implementation has met barriers, including cost and resources for administration. The TLC-ART program, a public-private partnership, engineered a novel 3-drug combination nanoparticle (DcNP) for subcutaneous injection containing lopinavir (LPV), ritonavir (RTV), and tenofovir (TVF) “TLC-ART 101” bound…

643 – Modeling Accurately Predicts Efficacious Islatravir QW Dose With No Lymphocyte and CD4 Changes

Background Islatravir (ISL) is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) being studied for HIV-1 treatment. Exposure-related decreases in total lymphocyte and CD4+ T-cell counts were observed across ISL clinical trials, with greater changes observed in ISL higher-dose regimens. Models that describe changes in lymphocytes and CD4+ T-cells in relation to intracellular ISL-triphosphate (TP) concentrations…

649 – Reduced Metformin Concentrations in Obese Women With HIV Treated With Dolutegravir

Background The prevalence of obesity among women with HIV (WWH) is nearly 2-fold higher than in men with HIV, especially in sub-Saharan Africa. Obesity is closely associated with dysglycemia, and in the context of HIV frequently necessitates the co-administration of the first-line antiretroviral dolutegravir (DTG) and the insulin sensitizer metformin. However, a drug interaction exists…

644 – Can “Equivalence” of a Generic Cabotegravir LA Be Inferred From a Shortened Pharmacokinetic Study?

Background Long acting injectable (LAI) antiretrovirals hold enormous potential for treatment and prevention of HIV in low- and middle-income countries (LMIC) but significant access challenges exist. One obstacle for generic LAIs is the assessment of “equivalence” with originator products. Accepted standards of bioequivalence for oral generic products may be sub-optimal because small differences may be…